HighTower Advisors
INDV icon

HighTower Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

HighTower Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Buy
+10,218
New +$337K ﹤0.01% 3146

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HighTower Advisors's INDV Position: Q1 2026 in Review

HighTower Advisors opened a new position in Indivior Pharmaceuticals (INDV) in Q1 2026: 10,218 shares worth $311K. The stake represents ﹤0.01% of the portfolio and ranks #3146 among its holdings.

289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • HighTower Advisors held 10,218 shares of Indivior Pharmaceuticals worth $311K as of Q1 2026.
  • Indivior Pharmaceuticals was a new HighTower Advisors position in Q1 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3146 holding.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.